Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ACTRN12626000899347) titled 'Study to Evaluate Safety, Tolerability and PK of study drug SLTE-1009 in Healthy Adult Patients' on July 21.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Slate Medicines
Condition:
Migraine
Migraine
Neurological - Other neurological disorders
Intervention:
Part 1: Single Ascending Dose (SAD) part will be conducted as a placebo-controlled single dose study to assess the safety, tolerability, and PK of a single dose of SLTE-1009 administered in healthy adult participants. Participants will be randomized in a 3:1 ratio per cohort (n=8) ...